Flow cytometry profiling of circulating T cells in patients with breast cancer after short- and long-term venetoclax treatment reveals limited changes in T-cell subsets. (A) Schematic representation of immunophenotyping of the patients with breast cancer receiving long-term venetoclax treatment. Blood was collected from patients with breast cancer before (pre) and after (post) venetoclax treatment (median treatment, 88.6 weeks; range, 8.8-204.2 weeks). Pre- and posttreatment cells from each patient were analyzed by flow cytometry (n = 13 pairs). (B) Bar graphs show the study duration, early clinical benefit, dose of venetoclax, and analysis time point for each patient. (C) Concentration of lymphocytes, B cells, NK cells, and T cells. Percentages of CD45RA⁺CCR7⁺ naïve (N), CD45RA⁻CCR7⁺ CM, CD45RA⁻CCR7⁻ EM, and CD45RA⁺CCR7⁻ effector (EMRA) cells from CD4 (C) and CD8 (D) T cells measured by flow cytometry (bottom). (D) Schematic representation of the longitudinal immunophenotyping of the patients with breast cancer who received short-term venetoclax treatment. Blood was collected at 4 different time points and analyzed by flow cytometry (n = 4 sets). (E) Bar graphs show the time points analyzed, early clinical benefit, and dose of venetoclax for each patient in panel F. Measurements were made at pre- and post- (6, 8, and ≥12 weeks on venetoclax treatment). (F) Dot plots show concentrations of B cells, NK cells, and T cells. Percentages of CD45RA⁺CCR7⁺ naïve, CD45RA⁻CCR7⁺ CM, CD45RA⁻CCR7⁻ EM, and CD45RA⁺CCR7⁻ effector (EMRA) cells from CD4 (C) and CD8 (D) T cells were measured by flow cytometry. Lym, lymphocyte; WBC, white blood cell.